title: Does pregnancy affect the pharmacokinetics of efavirenz?
authors.affiliation: aDepartment of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK bWorld Health Organization, Geneva, Switzerland cChelsea and Westminster Hospital, London, UK dProgram for HIV Prevention and Treatment (IRD UMI 174), Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand eDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Nathan
authors.initials: N
authors.lastname: Ford
authors.forename: Marta
authors.initials: M
authors.lastname: Boffito
authors.forename: Anton
authors.initials: A
authors.lastname: Pozniak
authors.forename: Tim R
authors.initials: TR
authors.lastname: Cressey
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D048588:Benzoxazines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; C098320:efavirenz